Effect of High-Intensity Focused Electromagnetic Therapy on Balance and Quality of Life in Patients With Multiple Sclerosis

NCT07646912 | Not Yet Recruiting DMC

• 1 other identifier: Electromagnetic Intervention
• Study Type: interventional
• Target: 60
• Locations: 0 countries
• Sites: N/A

Brief Summary

Evaluate the effect of High-Intensity Focused Electromagnetic Therapy on dynamic balance, fall risk, core muscle function, and quality of life in patients with multiple sclerosis.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

• Balance

  Berg Balance Scale will be used to assess balance. A 14-item objective clinical rating scale evaluating functional balance performance (e.g., reaching, turning, standing on one leg). Scores range from 0 to 56, where higher scores indicate better balance control.

  Baseline and after 8 weeks

Secondary Outcomes (3)

• Health-Related Quality of Life

  Baseline and after 8 weeks

• Risk of Fall

  Baseline and after 8 weeks

• Core Muscle Function

  Baseline and after 8 weeks

Study Arms (2)

Experimental group

ACTIVE COMPARATOR

Patients with multiple sclerosis who will receive High-Intensity Focused Electromagnetic Therapy targeted at the abdominal and paraspinal core musculature, combined with a specialized balance training program for 8 weeks

Device: High-Intensity Focused Electromagnetic Therapy; Other: Balance Exercises

Control group

ACTIVE COMPARATOR

Patients with multiple sclerosis who will receive the standardized balance training program alone for 8 weeks.

Other: Balance Exercises

Interventions

High-Intensity Focused Electromagnetic Therapy DEVICE

For 8 weeks, two weekly sessions of High-Intensity Focused Electromagnetic Therapy will be used to induce supramaximal contractions to strengthen the central core stabilizers (rectus abdominis, transversus abdominis, and erector spinae)

Experimental group

Balance Exercises OTHER

Standardized balance training including static stance variations, dynamic weight-shifting, perturbation training, and functional gait adjustments will be conducted for 30-45 minutes per session through three weekly sessions for a total duration of 8 weeks.

Control group; Experimental group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64)

You may qualify if:

• Confirmed clinical diagnosis of Multiple Sclerosis according to the revised McDonald criteria.
• Expanded Disability Status Scale score range between 3.0 and 5.5.
• Clinically stable condition with no neurological relapses or corticosteroid therapy within the past 3 months.

You may not qualify if:

• Presence of pacemakers, internal defibrillators, or metallic implants in the torso/abdominal region.
• Severe cognitive impairment interfering with the understanding of instructions or questionnaires.
• Other concomitant neurological or musculoskeletal orthopedic conditions that independently affect balance or gait.
• Severe visual deficits or uncorrected vestibular disorders.
• Pregnancy.

Sponsors & Collaborators

• Middle East University: lead

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Saher Lotfy Elgayar, Ph.D

CONTACT

+201020429911; saherlotfy020@gmail.com

Mohammed Youssef Elhamrawy, Ph.D

CONTACT

+201282805567

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant Professor of Physiotherapy

Study Record Dates

• First Submitted: June 9, 2026
• First Posted: June 15, 2026
• Study Start (Estimated): June 22, 2026
• Primary Completion (Estimated): October 8, 2026
• Study Completion (Estimated): October 14, 2026
• Last Updated: June 15, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share